Market Research Blog – Page 339 – New Product Development

Global Hormone Replacement Therapy (HRT) Industry Forecasted to Reach USD 23,729.6 Million by 2034, Driven by Increased Awareness and Government Initiatives

The global hormone replacement therapy industry is set to experience significant growth, with its value projected to climb from USD 16,825.2 million in 2024 to an estimated USD 23,729.6 million by 2034. This expansion, marked by a steady compound annual growth rate (CAGR) of 3.50%, reflects a strong industry trajectory fueled by heightened awareness and supportive government policies.

A key driver behind the rising adoption of HRT is the growing awareness of hormone disorders and deficiencies through targeted efforts by organizations, social media campaigns, and influencer outreach. Notably, initiatives like those of the Child Growth Foundation are making substantial strides in improving the lives of individuals with rare growth hormone disorders. By disseminating crucial information and support to patients, caregivers, and healthcare providers, these organizations are elevating patient outcomes and building a foundation of understanding around hormone therapies.

Further supporting the expansion of the HRT market are governmental actions that reduce the financial burdens on individuals. In a recent example, the United Kingdom launched a pioneering scheme aimed at assisting women experiencing menopausal symptoms, enabling them to save on prescription charges annually. Such financial support initiatives are becoming increasingly common and are anticipated to further stimulate the demand for HRT globally.

Looking forward, major players in the HRT market are poised to focus on emerging markets with high population density. Recognizing oral ingestion as the most commonly prescribed method of administration, these companies are investing in production upgrades and targeted research to maintain and enhance their market positions. “Ongoing trends suggest that key players are likely to shift their focus to emerging economies with a high population density. By optimizing production and investing in research, these players can sustain growth and better serve these markets,” says an analyst at Future Market Insights.

As awareness continues to spread and support from governments grows, the global hormone replacement therapy market is positioned to achieve remarkable growth, benefiting millions worldwide.

Key Takeaways from the Hormone Replacement Therapy Industry Report:

The market witnessed a CAGR of 4.1% in the historical period, in contrast to the 3.5% CAGR estimated for the forecast period.
The United States is projected to lead the market in North America. The United States is projected to register a CAGR of 1.6% through 2034, as per analysis by FMI analysts.
Within Europe, the United Kingdom and Germany are important hormone replacement therapy industry. The United Kingdom is predicted to register a CAGR of 2.3%, whereas Germany is predicted to expand at a CAGR of 2.1% through 2034.
Within Asia Pacific, China and India are significant markets lifting the regional market’s value over the next 10 years. India is expected to record a CAGR of 5.2%, while China is anticipated to record a CAGR of 4.5% through 2034.
Based on the therapy area, estrogen replacement therapy is expected to garner a market share of 38.9% in 2024.
Based on dosage form, the oral tablets/capsules are anticipated to acquire a value share of 43.2% in 2024.

Heightened Demand for Market Data: Our Full Report Provides Extensive Trend Analysis!

Key Steps Undertaken by Market Players to Grab Greater Share in the Market:

Leading players in the HRT market are consolidating their positions by joining partnerships. Players are also strategizing for mergers and acquisitions to increase their market share. Market participants are projected to assert product approvals to gain a broader patient base. With significant investment allocated for research and development, market players are expected to change the shape of hormone replacement therapy industry in upcoming years.

Recent Developments Punctuating the HRT Market:

In September 2023, LifeMD, Inc. partnered with ASCEND Therapeutics US, LLC to debut an integrated direct-to-consumer telehealth model to enjoy improved access to EstroGel.
In April 2023, GOV.UK published on its site that from this day onward, women residing in England are expected to access hormone replacement therapy (HRT) in an affordable price range. This is expected to increase the accessibility of this therapy.

Prominent Companies in the Hormone Replacement Therapy Market are as Follows:

Eli Lilly and Company
Bayer AG
Noven Pharmaceuticals, Inc.
Pfizer Inc.
Merck & Co., Inc.
Viatris, Inc.
Novo Nordisk A/S
F. Hoffmann-La Roche Ltd.
ASCEND Therapeutics US, LLC.
AbbVie, Inc.
Others

Key Market Segments Covered in Global Hormone Replacement Therapy Industry Research:

By Therapy Type:

Estrogen Replacement Therapy
Growth Hormone Replacement
Dopamine Agonist
Somatostatin Analogues
Thyroid Hormone Replacement

By Route of Administration:

Oral Tablets/Capsules
Parenteral
Transdermal
Others

By Disease Type:

Menopause
Hypothyroidism
Male hypogonadism
Growth hormone deficiency
Hypoparathyroidism

By Region:

North America
Latin America
East Asia
South Asia and Pacific
Western Europe
Eastern Europe
The Middle East and Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Generic Injectable Industry Set to Soar, Projected to Reach USD 322,433.1 Million by 2033

The global generic injectable industry is poised for extraordinary growth, with recent forecasts predicting a staggering market value of USD 322,433.1 million by 2033. According to the latest analysis, the sector is expected to experience a robust Compound Annual Growth Rate (CAGR) of 11.6% from 2023 to 2033, starting from a projected valuation of USD 107,419.72 million in 2023.

This remarkable surge in market demand is largely attributed to the increasing prevalence of chronic diseases, which is driving substantial investments in innovative healthcare solutions, particularly within the generic injectables segment. As chronic conditions such as diabetes and cardiovascular diseases become more widespread, the need for rapid and effective treatment options, particularly through intravenous (IV) and intramuscular (IM) routes, has intensified. A prime example of this trend is the use of intramuscular insulin administration, which has demonstrated significant improvements in patient outcomes and is a major factor fueling market expansion.

In addition to the rise in chronic illnesses, the healthcare industry is undergoing a significant shift towards more efficient treatment methodologies. Generic injectables provide a cost-effective, timely solution for administering life-saving medications, helping to meet the growing healthcare demands of diverse populations across the globe.

The market’s unprecedented growth is further supported by advancements in pharmaceutical technology and increased healthcare spending worldwide. Industry leaders are investing heavily in research and development to introduce innovative and enhanced injectable formulations that cater to the evolving needs of patients and healthcare providers alike.

With chronic disease management becoming an ever-pressing global concern, the demand for generic injectables is expected to continue its upward trajectory, transforming the landscape of modern healthcare and offering new hope for more effective and accessible treatment options.

Key Takeaways from Generic Injectable Market Study:

The U.S. is estimated to emerge as a highly attractive market, accounting for more than 29% of the overall sales during the assessment period.
France is projected to hold a significant share in the Europe market, exhibiting sales growth at 12% year-over-year growth in 2021.
The sales in the U.K. are anticipated to rise at 11% year-on-year, owing to the increasing prevalence of lifestyle diseases such as diabetes in the country.
On the basis of molecule type, the large molecule type segment is forecast to dominate the market, accounting for nearly 57% of the value share through 2031.
In terms of application, the diabetes segment is projected to register the fastest growth in the segment, expanding at a massive CAGR of 12% over the forecast period.

Key Drivers:

Increasing prevalence of chronic diseases such as cancer in countries such as the U.S., China, India, Germany, Japan, and others is propelling the demand for generic injectable in the chemotherapy agent segment.
Rising adoption of intravenous injections by doctors owing to their ease of operations, lower cost, and better results on the treatment of number of life treating diseases and associated therapeutics are increasing the sales across in the intravenous segment.

Key Restraints:

Need for complex equipment, appropriate certification, and sterilization standards for manufacturing generic injectables is hampering the growth in the market.
Stringent regulatory approvals policies and mandates of maintaining high degrees of care while manufacturing, packaging, storage, and distribution are restricting the growth of the market.

High Demand for Market Insights: Discover Comprehensive Trends in Our Full Report!

Competitive Landscape:

Leading players in the global generic injectable industry are focusing on strengthening their market footprint by adopting strategies such as partnership, strategic collaboration, merger, and acquisition with various other organization. For instance,

In January 2020, Merck, an American multinational pharmaceutical company, announced entering into a strategic collaboration with a Japanese pharmaceutical company, Taiho Pharmaceutical Co, Ltd, to emphasize on the development of small molecule injection inhibitors in cancer research for oncology platform.
In March 2021, a leading pharmaceutical company, Pfizer Inc. and Eli Lilly and Company, an American pharmaceutical company, announced receiving an U.S. Food and Drug Administration (FDA) approved for their new product tanezumab, for treating osteoartities pain.

Key Players Operating In The Market Profiled By FMI Are:

Samsung Biologics Co Ltd
Aurobindo Pharma Limited
Sun Pharmaceutical Industries Ltd.
Novartis AG
Merck & Co. Inc.
Cipla Ltd
Pfizer Inc
Fresenius Kabi
Sanofi S.A
AstraZeneca Plc
Teva Pharmaceuticals.
Mylan N.A
Baxter International
Dr. Reddy’s Laboratories Ltd

More Valuable Insights on Generic Injectable Industry:

A detailed report published by FMI offers an unbiased analysis of the global generic injectable industry, forecasting sales and demand statistics through 2021 and beyond. The survey reveals growth projections on in generic injectable market with detailed segmentation:

By Product type:

Monoclonal Antibodies Generic injectable
Immunoglobulin Generic injectable
Cytokines Generic injectable
Insulin Generic injectable
Peptide Hormones Generic injectable
Blood Factors Generic injectable
Peptide Antibiotics Generic injectable
Vaccines Generic injectable
Small Molecule Antibiotics Generic injectable
Chemotherapy Agents Generic injectable

By Molecule Type:

Small Molecule Generic injectable
Large Molecule Generic injectable

By Application:

Oncology Generic injectable
Infectious Diseases Generic injectable
Diabetes Generic injectable
Blood Disorders Generic injectable
Hormonal Disorders Generic injectable
Musculoskeletal Disorders Generic injectable
CNS Diseases Generic injectable
Pain Management Generic injectable
Cardiovascular Diseases Generic injectable

By Route of Administration:

Intravenous (IV) Generic injectable
Intramuscular (IM) Generic injectable
Subcutaneous (SC) Generic injectable

By Distribution channel:

Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Pharmacies

About Future Market Insights (FMI)

Contact Us:

Global DNA Synthesis Industry Poised for Significant Growth, Projected to Reach USD 9,999.6 Million by 2033

The global DNA synthesis industry is set to experience remarkable growth, with its valuation expected to increase from USD 2,898.3 million in 2023 to an impressive USD 9,999.6 million by 2033. The market is anticipated to grow at a compound annual growth rate (CAGR) of 13.2% during the forecast period, driven by ongoing advancements in technology, biotechnology, and genomics.

DNA synthesis, also known as gene synthesis or gene assembly, has emerged as a cornerstone technology across several industries, including genetic research, biotechnology, drug development, and personalized medicine. The artificial creation of DNA molecules with specific sequences has become indispensable in pushing the boundaries of scientific discovery, with applications ranging from gene therapy to synthetic biology.

The expansion of gene editing technologies has significantly accelerated the market’s growth, enabling more accurate, scalable, and cost-effective DNA production. The increasing demand for custom DNA sequences for research and therapeutic applications is further fueling this expansion. Next-generation gene synthesis technologies have revolutionized the field, offering unprecedented precision and efficiency that make DNA synthesis accessible to a wider range of industries.

One of the key areas propelling growth in the DNA synthesis industry is the rise of gene therapy and gene editing technologies. As the need for precise genetic modifications becomes more crucial in therapeutic interventions, DNA synthesis plays an essential role in enabling these advancements. This trend is expected to continue as researchers and clinicians explore new ways to treat and potentially cure genetic diseases.

Research and development (R&D) efforts remain a key driver in the DNA synthesis industry, contributing to 41.7% of market share. The ongoing focus on technological advancements, customization of DNA sequences, and collaborations with academic institutions continue to foster innovation in the field. These efforts are critical to meeting the growing demands of the life sciences industry.

Biopharmaceuticals represent another significant market segment, holding a dominant share of 44.2%. The increasing emphasis on biologics, gene therapies, and personalized medicine is fueling the demand for DNA synthesis, particularly in the development of DNA vaccines, monoclonal antibodies, and other therapeutic applications.

As the field of genomics and personalized medicine continues to evolve, the DNA synthesis market is poised for continued advancements and applications. The technology is set to remain a pivotal player in shaping the future of biotechnology and life sciences, offering new solutions to some of the world’s most pressing health challenges.

Key Takeaways:

North America leads the DNA synthesis industry, holding over 41.0% share during the forecast period. The region dominates due to the increasing use of gene therapy-based medications.
Europe presents substantial growth opportunities for DNA synthesis, expected to reach a share of 31.4%. The growth is attributed to increased research and development for gene synthesis used in vaccine preparation.
India is witnessing transformative growth in the DNA synthesis industry, with an expected growth rate of 18.1%. The country’s biotechnology and life sciences sectors are driving demand, supported by a flourishing biotech startup ecosystem, government initiatives, cost-effective services, and access to skilled workforce.

Growing Market Interest: Explore Comprehensive Insights and Trends with Our Detailed Report!

Competitive Landscape:

Leaders in the DNA Synthesis Market:

Key players in the DNA synthesis industry are driving growth to new heights with their strategic efforts. These industry leaders are recognized for their exceptional expertise and employ a variety of marketing strategies to maximize revenue. Through partnerships, collaborations, and other innovative approaches, these market leaders have been expanding their influence and advancing market growth in recent years.

Recent Developments:

Ribbon Biolabs earned a United States Patent in July 2022 for its process for synthesizing nucleotide molecules using a range of oligonucleotides. The approach contains a pre-built library of oligonucleotides for ease of use.
The AccuLoaderTM, a unique concept auxiliary device announced by BIONEER Corporation in February 2021, is designed to speed up sample preparation by assisting in distributing samples and reagents into the right wells.
LGC’s genomics division stated in November 2018 that it is rebranding as LGC Biosearch Technologies, a portfolio brand that merges optimized genetic analysis techniques and technology to accelerate scientific outcomes.

Key Companies Profiled:

Brooks Automation, Inc. (GENEWIZ); Boster Biological Technology; ProteoGenix; Biomatik; ProMab Biotechnologies, Inc; Thermo Fisher Scientific, Inc; Integrated DNA Technologies, Inc; OriGene Technologies, Inc

Key Segments Covered in the Market Report:

By Service Type:

Oligonucleotide
Universal Oligonucleotide
Custom Oligonucleotide
Gene
Custom Gene
Gene Library

By Application:

Research and Development
Academic Applications
Industrial Applications
Diagnosis
Therapeutics

By End User:

Biopharmaceutical Companies
Academic and Research Institutes
Contract Research Organizations

By Region:

North America
Latin America
Western Europe
Eastern Europe
Asia Pacific Excluding Japan (APEJ)
Japan
The Middle East & Africa (MEA)

About Future Market Insights (FMI)

Contact Us:

Global Veterinary Ultrasound Scanner Industry Set for Robust Growth, Projected to Reach USD 284.8 Million by 2033

The global veterinary ultrasound scanner industry is poised for significant growth, with forecasts predicting a substantial increase in market value over the next decade. As of 2023, the market is set to reach USD 198.1 million, and experts anticipate a steady Compound Annual Growth Rate (CAGR) of 3.7%, positioning the market to soar to USD 284.8 million by 2033.

Key Market Trends and Innovations:

The veterinary ultrasound market is experiencing a surge in demand, driven by cutting-edge technological advancements. One notable innovation is the integration of wireless streaming capabilities in devices like the IBEX® PRO and LITE models, which offer enhanced portability and convenience for veterinarians in the field. These advances allow for real-time, high-quality diagnostics in remote locations, making ultrasound technology more accessible than ever.

Additionally, specialized tools such as the OsiriX® viewer, developed specifically for dogs, are revolutionizing diagnostic accuracy. By enabling highly precise and reproducible CT prostate volume assessments, these technologies help minimize human observation errors, ensuring more accurate diagnoses and improving treatment outcomes for animals.

Market Growth Factors:

While the market did experience a slowdown during the first half of the forecast period—largely due to slow adoption of ultrasound technology and challenges like the COVID-19 pandemic’s impact on pet adoption rates—the industry is now regaining momentum. Technological improvements and growing awareness of animal healthcare’s importance are key drivers of this resurgence. Veterinarians worldwide are increasingly adopting advanced diagnostic tools, contributing to the market’s recovery and ongoing expansion.

The rising global number of pet owners further fuels demand for veterinary diagnostic tools, creating a favorable environment for market growth. As pet care continues to be a top priority for many, the need for reliable, accurate diagnostic tools is greater than ever.

Looking to the Future:

The future of the global veterinary ultrasound scanner industry looks promising. With a projected market value of USD 284.8 million by 2033, industry leaders remain optimistic about the continued adoption of innovative technologies that enhance diagnostic precision. This, combined with a growing focus on animal healthcare, is set to drive the market forward and ensure steady growth over the next decade.

As the veterinary ultrasound scanner market evolves, it will play a crucial role in advancing animal healthcare by equipping veterinarians with the tools necessary to provide more accurate, efficient, and reliable diagnostics, ultimately benefiting both animals and their owners worldwide.

Key Takeaways from the Market Study:

The market valuation in 2022 was USD 9 million.
Based on product type, portable/handheld ultrasound scanners are expected to dominate at a market share of 86.5% in 2023.
Based on imaging technology, digital imaging technology will register at a market share of 93.7% in 2023.
The veterinary ultrasound scanner industry size expanded at 4.6% CAGR between 2018 and 2022.
India is estimated to expand at a CAGR of 5.5% by 2033.
Germany experiences a significant rise, with a CAGR of 2.2% by 2033.

“Technological advancements have largely influenced the veterinary care market and also affected the veterinary ultrasound scanner demand is thus considered one of the major drivers of the veterinary ultrasound scanner industry,” comments a Future Market Insights analyst.

Unveil the Veterinary Ultrasound Scanner Surge: Read Our Detailed Report for Essential Trends and Insights!

Drivers of Growth:

Increased awareness and importance of animal healthcare: This includes rising pet ownership, growing concern about zoonotic diseases (diseases transmissible between animals and humans).
Technological advancements: Advancements in ultrasound technology lead to more accurate and efficient diagnoses.
Rising expenditure on animal health: Pet owners are spending more on their pets’ well-being, including diagnostics.
Pet insurance adoption: Increased pet insurance allows for more comprehensive veterinary care, including ultrasound scans.
Government initiatives: Supportive government programs promoting animal health can contribute to market growth.

Competitive Landscape:

The veterinary ultrasound scanner industry boasts a substantial array of market participants. Research and development play a pivotal role among these players, primarily focusing on introducing eco-friendly product lines as a core aspect of their manufacturing endeavors. Furthermore, they employ various expansion strategies, including collaborations, mergers and acquisitions, and diligent exploration of regulatory approvals to bolster their market presence.

Some of the key developments are-

Butterfly Network Inc., a trailblazing digital health firm recognized for its innovative product approach, recently unveiled its latest veterinary ultrasound device. The iQ+ Vet ultrasound introduces a cutting-edge guidance tool and hardware enhancements, promising sharper imaging for improved diagnostics.
Lacuna Diagnostics Inc., a pioneering telemedicine and point-of-care diagnostics company, entered into a comprehensive acquisition agreement with Heska Corporation.

Key Companies Profiled:

Siemens AG
Mindray Medical International Limited
Hitachi Ltd.
Fujifilm Holdings Corporation
General Electric Company
Canon Inc.
Samsung Electronics Co. Ltd.
Esaote SpA
DRAMI?SKI S. A.
IMV Technologies SA

Key Segments of Veterinary Ultrasound Scanners Industry Survey:

By Product Type:

Portable/Hand Held Ultrasound Scanners
Cart Based Ultrasound Scanners

By Imaging Technology:

Digital Imaging Technology
Analog Imaging Technology
Contrast Imaging Technology

By End User:

Veterinary Hospitals
Veterinary Clinics
Animal Breeding and Farms

By Region:

North America
Latin America
Western Europe
Eastern Europe
South Asia and Pacific
East Asia
The Middle East & Africa

About Future Market Insights (FMI)

Contact Us:

Global HLA Typing Industry to Reach USD 2.1 Billion by 2033, Driven by Surge in Transplant Treatments and Advances in Molecular Assays | FMI

Global estimates suggest the global HLA typing industry is currently valued at USD 1.1 billion and is poised for significant growth over the next decade. Expected to expand at a steady compound annual growth rate (CAGR) of 6.7% from 2023 to 2033, the market is projected to reach a valuation of USD 2.1 billion by 2033.

The growth of the HLA typing industry is primarily fueled by the increasing demand for organ transplants. With the rise in chronic and infectious diseases globally, the need for precise and reliable HLA typing for organ compatibility has never been more critical. Additionally, advancements in molecular assays are enhancing the efficiency and accuracy of HLA typing, further propelling market growth.

Key Factors Driving Market Expansion:

Increase in Organ Transplants: The growing number of transplant procedures worldwide is a key driver for the HLA typing industry, as matching organ donors with recipients through accurate HLA typing is vital to the success of transplants.
Rising Prevalence of Chronic and Infectious Diseases: The global rise in chronic conditions, such as kidney and heart diseases, along with an increase in infectious diseases, has led to a surge in demand for organ transplants, subsequently boosting the need for HLA typing.
Technological Advancements in Molecular Assays: Innovations in molecular techniques for HLA typing are improving the accuracy and speed of the process, thereby supporting market growth. These advances allow for more precise organ matching, minimizing rejection risks and improving transplant success rates.
Increased Funding for Research: The growing availability of research funding for HLA typing technologies is expected to further drive market growth, supporting the development of more advanced solutions in the field.
Heightened Public Awareness: Increasing public awareness about organ donation and its importance in saving lives presents new opportunities for market growth, with more individuals becoming educated on the necessity of HLA typing in the donation process.

The market is also set to benefit from a wider acceptance of HLA typing as a critical tool not only in organ transplants but also in other areas such as autoimmune disease management, tissue matching, and personalized medicine. The future of HLA typing is thus shaped by both medical advancements and societal shifts towards greater healthcare awareness.

As the market continues to expand, key players in the healthcare and diagnostics sectors are poised to innovate, driving further developments and bringing improved solutions to the global HLA typing landscape.

Enhanced Interest in Market Trends: Access In-Depth Analysis and Insights with Our Full Report!

Competitive Landscape of the HLA Typing industry:

HLA typing plays a pivotal role in modern healthcare, offering significant advantages such as enhanced organ transplantation outcomes, personalized treatment options, improved disease diagnosis, and valuable research opportunities. Leading players in the HLA typing market include Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Qiagen N.V., Omixon Inc., GenDx, and Illumina Inc. These companies leverage both organic and inorganic growth strategies to expand their market presence and consumer base.

Recent Developments in the HLA Typing industry:

In October 2023, Eurobio Scientific’s GenDx subsidiary launched the NGS-Turbo, a cutting-edge solution designed for Research Use Only (RUO). This technology integrates Oxford Nanopore Technologies sequencing devices, offering unmatched speed and efficiency in HLA typing, particularly when time is of the essence.
Additionally, Omixon Inc. introduced the NanoTYPE RUO Multiplex Human Leukocyte Antigen Amplification Kit in September 2023. This new kit is now compatible with the Oxford Nanopore MinION Platform, further advancing the capabilities of HLA typing technology.

Key Companies in the HLA Typing industry:

Thermo Fisher Scientific Inc.
Bio-Rad Laboratories Inc.
Qiagen N.V.
Omixon Inc.
GenDx
Illumina Inc.
F.Hoffmann-La Roche Ltd.
Immucor, Inc.
bioMerieux S.A.
CareDx, Inc.
Hologic, Inc.
Olerup International AB

Market Segmentation:

By Product Type:

Instruments
Reagents & Consumables
Software & Services

By Application:

Diagnosis
Research

By Technique:

Molecular Assay
Sequenced-based Molecular Assay
Non-molecular Assay

By End User:

Commercial Service Providers
Hospitals
Transplant Centers
Research Labs
Academic Institutes

By Region:

North America
Europe
Asia Pacific
Latin America
The Middle East & Africa

About Future Market Insights (FMI)

Contact Us:

Global Asthma Treatment Industry is set to reach USD 46.0 Billion by 2034 at a 5.1% CAGR | Future Market Insights

According to Future Market Insights (FMI), the global asthma treatment industry is poised for substantial growth, projected to hit USD 28.0 billion in 2024 and soar to USD 46.0 billion by 2034, with a Compound Annual Growth Rate (CAGR) of 5.1% by 2034.

The burgeoning prevalence of asthma worldwide, coupled with a heightened awareness of asthma medications and advancements in treatment options, is anticipated to propel market expansion. Factors such as air pollution, allergens, and lifestyle changes are contributing to the increased incidence of asthma, thereby bolstering market growth.

One of the key drivers of growth in the asthma treatment industry is the adoption of precision medicine, as demand for personalized asthma medications surges. Innovations such as mobile applications, smart inhalers, and wearable devices are revolutionizing tailored asthma therapy by enabling real-time monitoring of symptoms, medication adherence, and lung function.

This precise data collection empowers healthcare practitioners to better understand each patient’s asthma management and tailor treatment solutions accordingly. Additionally, remote monitoring and telemedicine services are expected to enhance personalized treatment, particularly for patients in remote and underdeveloped areas.

Pharmaceutical companies and research organizations are heavily investing in developing new drugs and therapies to address the diverse needs of asthma patients worldwide. Public health initiatives and awareness campaigns are further catalyzing market development, with factors such as urbanization, industrialization, genetic susceptibility, and family history of asthma contributing to the escalating prevalence of the condition.

The global asthma treatment industry is on a trajectory of robust growth, driven by factors ranging from technological innovations to environmental influences. As the industry continues to evolve, stakeholders are focused on addressing the evolving needs of asthma patients and advancing treatment options to improve patient outcomes worldwide.

Key Takeaways from the Asthma Treatment Market Report:

The asthma treatment market is set to reach a valuation of USD 46.0 billion by 2034.
The market is projected to surge at a CAGR of 5.1% by 2034.
China’s asthma treatment industry is anticipated to grow at a CAGR of 5.9% by 2034.
The United States is projected to reach a valuation of USD 8.3 billion in 2034.
Based on product, the inhaler segment is set to rise at 4.8% CAGR by 2034.

“AI and machine learning algorithms are being developed to analyze large datasets and identify patterns in asthma management, assisting in optimizing treatment plans and personalizing therapy based on patient characteristics. AI-based tools also aid in the interpretation of diagnostic tests, facilitating faster and more accurate diagnosis, propelling the market.” – opines Sabyasachi Ghosh Associate Vice President at Future Market Insights (FMI).

Increased Market Insight Demand: Get Thorough Analysis and Trends in Our Complete Report!

Competitive Landscape:

The market is competitive, with various providers vying for market share. Key factors include product efficiency, pricing, supply chain, and technological innovations.

Established pharmaceutical companies are directed toward research and development to maintain their market power, while emerging biotech companies innovate with targeted treatments. Market expansion relies on regulatory adherence, diagnostic research, strategic partnerships, and adapting to evolving consumer tastes.

For instance,

In July 2023, Teva Pharmaceuticals partnered with Alvotech, enabling Teva to commercialize new biosimilars in the United States and acquiring USD 40 million in convertible bonds to support Alvotech’s pipeline development.

Key Companies Profiled:

Teva Pharmaceutical Industries Ltd.
GSK plc
Merck & Co., Inc.
F. Hoffmann-La Roche Ltd.
AstraZeneca
Boehringer Ingelheim International GmbH
Sanofi.
Koninklijke Philips N.V.
BD
Covis Pharma

Asthma Treatment Industry Segmentation by Category:

By Drug Class:

Anti-inflammatory
Bronchodilators
Combination Therapy

By Product:

Inhalers
- Dry Powder
- Metered Dose
- Soft Mist
Nebulizers

By Route of Administration:

Oral
Inhaled
Others

By Region:

North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East and Africa

About Future Market Insights (FMI)

Contact Us:

Global Pain Management Device Industry Projected to Surpass USD 5.68 Billion by 2032

The global pain management device industry is set for remarkable expansion, with projections indicating it will surpass a market valuation of USD 5.68 billion by the end of 2032, according to the latest report from Future Market Insights (FMI). This growth trajectory is underlined by a strong 9% Compound Annual Growth Rate (CAGR) expected between 2022 and 2032.

Cost-Effective Healthcare Solutions Driving Market Growth

With rising healthcare costs and the increasing financial burden of hospitalization there is a significant shift towards more economical alternatives. Pain management devices are leading the way, providing effective solutions to alleviate pain without necessitating extended hospital stays. This trend is playing a crucial role in the market’s ongoing expansion, as more healthcare providers adopt these devices to enhance patient care while minimizing costs.

Surgical Procedures Fueling Demand for Pain Management Devices

According to data from the National Center for Biotechnology Information (NCBI), over 51 million inpatient surgical procedures take place annually in the United States alone, with nearly 90% of hospitalized patients receiving medication via IV. This highlights a growing need for devices like infusion therapy equipment, as surgeries and post-operative care continue to rise. The surge in surgeries directly correlates with increased sales of pain management devices, further bolstering market growth.

Technological Advancements and Market Trends

In addition to the healthcare sector’s need for cost-effective solutions, technological innovations are reshaping the landscape. Advanced wearable pain management devices are gaining traction, offering patients new ways to manage chronic pain effectively. These innovations are particularly relevant in developing economies, where the market’s untapped potential provides lucrative opportunities.

However, challenges remain. Concerns about hypersensitivity reactions and the risk of postoperative infections associated with chronic pain relief devices are influencing adoption trends. Additionally, many pain relief devices are primarily used as a second-line treatment for patients who have developed resistance to drug therapy, making the market outlook uncertain.

Future Market Projections

Despite these challenges, the market’s overall trajectory remains positive. Driven by increasing demand in emerging markets and ongoing technological advancements, the pain management device industry is anticipated to reach a valuation of USD 3.3 billion by 2026, setting the stage for substantial growth in the years to come.

The future of pain management devices lies in the ability to address evolving patient needs with innovative, reliable, and cost-effective solutions, reinforcing their role as a vital component of modern healthcare.

Rising Interest in Market Trends: Our Detailed Report Provides Essential Insights!

Key Takeaways:

By application, neuropathic pain is expected to lead the market, owing to technological advancements in pain management machines and a surge in demand for pain management devices for the management of neuropathic pain.
The neuromodulation and neurostimulation devices segment is anticipated to come to the fore by-product because of the cost efficiency offered by these pain relief equipment and an increase in the target population.
Whereas, Radiofrequency ablation is expected to grow the fastest during the forecast period by-product due to its widespread use in pain management, surgical oncology, gynaecology & cardiac rhythm management, and cosmetology.
During the forecast period, the Asia Pacific market is expected to grow at the fastest CAGR, and this expansion can be attributed to R&D investments in the development of technologically advanced healthcare treatment options.

“North America has been a pioneer in the development of pain management devices and services in the healthcare industry. The United States market is expected to elicit several emerging trends in the pain management devices market in the near future, owing to the increasing incorporation of the best pain relief devices in ambulatory care centres and many major global players are also based in the United States, which has resulted in the country becoming a centre of innovation in the pain management device market.” opines Sabyasachi Ghosh Associate Vice President at Future Market Insights (FMI).

Competitive Landscape:

Medtronic is a significant global pain management devices market player. Medtronic is expected to maintain its market leadership due to its diverse product portfolio, strong distribution network, and strategic marketing policies. This company, along with Boston Scientific Corporation, currently controls the majority of the global market.

LivaNova, Abbott, Nevro Corp, and SPR Therapeutics are some of the other significant pain management medical device companies.

To strengthen their market position and pain management devices market share, the key companies have undertaken a number of strategic initiatives, including technological innovation, partnership, regional expansion, and mergers and acquisitions.

Some recent developments in the pain management devices market are as follows:

Smiths Medical has released version 4.2 of the CADD-Solis ambulatory infusion pump. This new version of the wireless bi-directional communication pump will aid in the integration of pain management data with the patient’s EMR records.
Boston Scientific has announced the release of Wave Writer Alpha, a Spinal Cord Stimulator (SCS) system designed to address pain management challenges. The SSC portfolio includes conditional devices that provide Fast Acting Sub-Perception Therapy (FAST), which is designed to provide pain relief in minutes.
Hinge Health, a Digital Musculoskeletal Clinic, announced the acquisition of the developer of Enso, a clinically validated non-invasive technology that aids people suffering from musculoskeletal pain. This merger of Hinge Health’s Digital MSK Clinic and Enso’s technology ushers in a new pain management devices era.

Key companies profiled:

Abbott Corporation (USA), Medtronic PLC (Ireland), Boston Scientific Corporation (USA), Stryker Corporation (USA), Becton, Dickinson and Company (USA), Baxter International (USA), Nipro Corporation (Japan), B. Braun Melsungen AG (Germany), Smiths Medical Corporation (USA), Moog Inc. (USA), Avanos Medical, Inc. (USA), Atricure Corporation (USA), Nevro Corporation (USA), and Micrel Medical Devices.

Key Segments:

By Type:

Neurostimulation Devices
Infusion Pumps
Ablation Devices

By Application:

Neuropathic Pain
Musculoskeletal Pain
Cancer Pain
Facial Pain & Migraine
Other Applications

By Mode of Purchase:

Prescription
Over-the-counter

By Region:

North America
Europe
Asia
Latin America
Middle East & Africa

About Future Market Insights (FMI)

Contact Us:

Global Golf Shoes Market Poised for Substantial Growth from 2024 to 2034, Driven by Rising Golf Participation and Technological Advancements

The global golf shoes market is set to experience significant growth over the forecast period, expanding from USD 8,815.9 million in 2024 to an estimated USD 14,303.4 million by 2034. This growth is primarily driven by the increasing number of golfers worldwide, along with an upsurge in golf tourism, the popularity of high-profile golf tournaments, and technological innovations in golf footwear. The industry is expected to exhibit a compound annual growth rate (CAGR) of 5% from 2024 to 2034.

Key Growth Drivers

Surge in Golf Participation: One of the most significant factors contributing to the growth of the golf shoes market is the rising participation rates in golf, especially among younger demographics and women. As golf continues to attract a more diverse player base, there is a noticeable shift in demand for specialized footwear to enhance performance and comfort on the course.
Technological Advancements: The adoption of lightweight, comfortable golf shoes with advanced features such as waterproofing, advanced grip technology, and smart sensors is driving demand. These innovations, which aim to improve both performance and style, are appealing to a broader range of golfers.
Sustainability Trends: With growing environmental awareness, there is a shift towards eco-friendly and sustainable golf shoes. Brands are increasingly incorporating recycled and biodegradable materials into their designs, aligning with global sustainability goals and offering a competitive advantage in the market. This trend is expected to fuel further growth, as consumers increasingly seek eco-conscious products.
Regional Demand and Market Variations: North America continues to dominate the global golf shoes market, owing to the strong golf culture and infrastructure. Europe follows closely behind, with the United Kingdom, Germany, and Sweden leading demand. Meanwhile, the Asia-Pacific region is also seeing steady growth, driven by the affluent middle class and growing interest in golf.

Segment-Specific Insights

Spiked or Cleated Golf Shoes: Spiked golf shoes are forecast to hold a 42.5% share of the market in 2024. Their superior traction, which provides stability and balance during the golf swing, makes them the preferred choice for golfers seeking optimal performance.
Synthetic Materials: Golf shoes made from synthetic materials are expected to dominate, with a market share of 18.7% in 2024. These shoes offer lightweight, breathable, and water-resistant properties, catering to golfers who play in varying weather conditions.

Emerging Trends and Innovations

Smart Technology Integration: The introduction of smart golf shoes equipped with sensors that monitor performance and provide real-time feedback is one of the most exciting developments in the sector. These innovations cater to tech-savvy golfers who seek personalized insights into their game.
Sustainability: Eco-friendly practices are becoming a key focus for many brands in the golf shoe industry. With the rise in consumer demand for sustainable products, manufacturers are increasingly using recycled materials and reducing carbon footprints in their production processes. This shift is helping brands align with consumer values and global environmental initiatives.
Demographic Shifts: Growing participation from women and junior golfers, as well as increasing golf tourism, are contributing to the market’s expansion. The trend toward promoting youth participation and offering golf shoes for junior players is also gaining momentum.

Regional Insights

United States: Golf footwear demand is bolstered by luxury resorts and a strong golf infrastructure, with steady growth expected.
Italy: Renowned for its high-quality craftsmanship and luxury fashion, Italy is projected to lead Europe with a 6.8% CAGR.
Japan: A significant player in the Asia-Pacific region, Japan’s extensive golf course network drives steady growth at a 6.5% CAGR.
Germany: Continues to show strong demand, supported by growing golf tourism and participation.
Australia: Golf footwear sales are increasing as the sport gains popularity, with a 5.5% CAGR forecast.

Competitive Landscape

Golf shoe manufacturers and suppliers are increasingly investing in the development of footwear made from sustainable materials, enhancing both durability and lightweight performance. In addition, leading companies are focusing on innovative designs, customizable features, and advanced adjustable soles that replace traditional models. As consumers seek cutting-edge technology and added benefits, retailers are responding by offering a diverse range of products in the golf apparel and footwear market.

Industry Update

On June 3, 2024, Jordan Brand unveiled the Air Jordan 9 Golf ‘US Open’ in a special colorway. Official images were released, marking a significant year for the Air Jordan 9, which features OG colorways and golf-specific designs set for a June 2024 release.
On June 2, 2024, Nike revealed the Air Pegasus 89 G ‘Accept and Embrace’ for the USA Open at Pinehurst. Inspired by North Carolina’s colors, the sneaker features dark and light blue shades, echoing Michael Jordan’s alma mater, aimed at casual fans and sneaker enthusiasts.
On May 31, 2024, Under Armour introduced the new UA SlipSpeed golf shoes, designed for dads. Alongside, they offered markdowns on new and featured sportswear, including outlet savings. Shoppers could find deals on men’s golf gifts, women’s shorts, kids’ shoes, new running shoes, and uncrushable hats.

Leading Golf Shoes Brands

Nike, Inc.
Adidas AG
FootJoy
Puma SE
Skechers USA, Inc.
Under Armour, Inc.
ECCO Sko A/S
Callaway Golf Company
New Balance Athletics, Inc.
ASICS Corporation
Mizuno Corporation
Acushnet Holdings Corp.
True Linkswear
Golfstream
Kikkor Golf

Get Connected with Our Expert Analyst on Email: sales@futuremarketinsights.com

Key Segments of Golf Shoes Market Report

By Product Type:

Spiked or cleated, spikeless, golf boots, and other product types are categorized in the golf shoes market.

By Material Type:

The golf shoe industry uses canvas, cotton, mesh, fabric, synthetic, rubber, leather, and other materials for making.

By Sole Type:

The segment is distributed to EVA, PU, Rubber, PVC, and other sole types.

By Consumer Orientation:

The sector is subdivided into male, female, and unisex.

By Sales Channel:

Direct sales/ exclusive stores, specialty stores, sports merchandise, departmental stores, online retailers, third-party consumers, direct-to-consumers, and other sales channels are included in this sector.

By Region:

A regional analysis has been carried out in key countries of North America, Latin America, Asia Pacific, Middle East and Africa (MEA), and Europe.

About Future Market Insights (FMI)

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube

Global Surgical Mask Industry Set for Robust Growth, Projected to Reach USD 5.7 Billion by 2033

The global surgical mask industry is on track for impressive growth, with a steady Compound Annual Growth Rate (CAGR) of 10.7% expected between 2023 and 2033. By the end of this period, the market is projected to surpass a significant market share of USD 5.7 billion, up from an estimated USD 2.06 billion in 2023.

Key factors driving this expansion include heightened awareness around the importance of mask-wearing, particularly in the wake of the ongoing health challenges presented by respiratory diseases. The healthcare sector’s rapid growth, coupled with an increase in surgeries, is further fuelling the demand for surgical masks globally. As healthcare professionals and the general public continue to prioritize health and safety, the need for protective masks remains high.

In addition to increasing demand, innovation in mask manufacturing is shaping the market’s future. Advanced fabric engineering is leading to the development of multi-layered, high-performance Personal Protective Equipment (PPE) masks. Manufacturers are focusing on creating reusable, sustainable, and highly protective solutions, which is further boosting the market’s appeal.

The rise of labeled surgical masks and the emergence of new coronavirus strains have also contributed to the growing market momentum. With the potential for future health crises, such as the spread of flu and other diseases, government regulations are encouraging continued mask usage, reinforcing the demand for surgical masks. Hospital staff, in particular, rely on disposable masks to safeguard against respiratory diseases, underlining their critical role in healthcare settings.

As the market adapts to both evolving healthcare needs and technological advancements, the surgical mask industry is poised for sustained growth, meeting the needs of healthcare professionals and the broader population alike.

Key Points:

The United States market is likely to lead the surgical mask industry in terms of market share. The market thrives at a CAGR of 10.9% during the forecast period. The market growth is attributed to higher government investments and the presence of prominent healthcare equipment brands like 3M. The regional market is expected to hold a value of USD 535.3 million by 2033.
The Canada surgical mask industry leads the market in terms of CAGR with a leading CAGR of 12.0% between 2023 and 2033. The regional growth is attributed to the aware citizens and stringent government norms. The market is anticipated to reach a value of USD 103.7 million by 2033.
The fluid/splash-resistant surgical mask segment is likely to thrive in the product type category as it thrives on a CAGR of 10.3 % between 2023 and 2033. The growth is attributed to its multi-purpose usage and popularity.
The hospital segment is expected to top the end-user category with a CAGR of 10.9% during the forecast period. The growth of this segment is garnered through higher investment and consumption along with government projects.

Expanding Market Need: Access Our Full Report for In-Depth Analysis and Trends!

Competitive Landscape:

The key vendors focus on adding layers to the mask while making their masks eco-friendly and sustainable for nature. Key competitors also merge, acquire, and partner with other companies to increase their supply chain, and distribution channel. The key players in the market are: Medline Industries, Inc., Thermo Fisher Scientific, Inc, Kindwell Medical, BioClean (ANSELL LTD.), Moldex-Metric Inc., Honeywell International Inc, Kowa Company, Ltd, and 3M

Recent Market Developments:

3M introduced its 3M 9501 + KN95 Mask for protection during surgeries. The mask also delivers healthcare particulate protection. It comes with an adjustable nose clip and comes with a knitted band with welded attachment.
Honeywell International Inc introduced its DC301 N95 disposable respirator with a nose clip. The mask comes with a humidity and moisture-resistant filter. It uses latex-free woven head straps that reduced the possibility of breakage.

Key Segments:

By Product:

Basic Surgical Masks
Anti-fog Foam Surgical Masks
Fluid/Splash Resistant Surgical Masks
Others

By End User:

Hospitals
Ambulatory Surgical Centers / Specialty Clinics
Individual
Others

Key Regions Covered:

North America
Latin America
Europe
Japan
Asia Pacific Excluding Japan
The Middle East and Africa

About Future Market Insights (FMI)

Contact Us:

Global Customizable Hair Dye Market Set for Strong Growth Driven by Personalization and Technological Advancements

The global market for customizable hair dye is projected to grow from USD 6,761.1 million in 2024 to USD 15,859.7 million by 2034, expanding at a robust compound annual growth rate (CAGR) of 8.9%, according to a new market report by [Company Name]. The surge in demand for personalized hair color s olutions is being driven by the growing trend of self-expression, technological advancements, and shifting consumer preferences across global markets.

Key Market Drivers

As consumers increasingly seek authenticity and individuality in their beauty choices, the haircare industry is experiencing a boom in customization. The trend of personalized beauty, seen predominantly in skincare, has extended to haircare, with customizable hair dyes offering consumers the ability to select colors, formulations, and styles that match their unique preferences and lifestyles.

The customizable hair dye market has benefited from advancements in technology, including virtual consultations, augmented reality (AR), and intuitive user interfaces that allow consumers to experiment with color choices in real-time. This technology gives consumers a hands-on experience in achieving their ideal hair color, enhancing overall satisfaction and expanding access to personalized products.

In addition, the growth of direct-to-consumer (DTC) brands has disrupted the traditional retail model, enabling hair dye companies to engage directly with customers. This change is empowering brands to offer a broader range of customizable options, fostering greater customer loyalty and stimulating industry growth.

Market Segmentation

Product Type: Permanent customizable hair dyes are expected to hold the largest market share in 2024, with a 27.3% share of the global market. Permanent dyes offer long-lasting color, superior gray coverage, and consistent results, which appeal to consumers seeking durability and vibrant, youthful-looking hair.
Form: Liquid customizable hair dye leads in terms of form, accounting for 59.2% of the market in 2024. Liquid dyes are popular for their ease of application, allowing for precise and even color distribution, making them ideal for at-home use. They also provide greater versatility, enabling users to mix colors and achieve personalized results.

Regional Insights

India: The customizable hair dye market in India is expected to grow at a CAGR of 12.7% through 2034, driven by rising urbanization, increasing disposable incomes, and the popularity of indie beauty brands. As consumers embrace global beauty trends and a preference for natural ingredients, the demand for customizable hair dye products is expected to continue its upward trajectory.
Singapore: In Singapore, the market is projected to expand at an 11.9% CAGR through 2034. The rise of beauty influencers and social media campaigns has fueled awareness and adoption of customizable hair dye products. Singapore’s fashion-conscious urban population is keen on experimenting with hair color, and eco-friendly products are gaining traction.
Japan: Japan is anticipated to experience significant growth at an 11.6% CAGR through 2034. The country’s dynamic fashion trends, including anime and Harajuku-inspired styles, along with the aging population’s preference for silver-haired solutions, have contributed to the growing demand for customizable hair dye.

Competitive Landscape

The customizable hair dye market is fiercely competitive, with L’Oréal S.A. standing out as a dominant player. The company leads the industry through its extensive product range, substantial investments in research and development, and robust global distribution network. L’Oréal capitalizes on its powerful brand and cutting-edge technologies to maintain continuous innovation.

At the same time, smaller, niche brands like Madison Reed Inc., Arctic Fox Hair Color, and eSalon.com LLC are shaking up the market by offering personalized, eco-friendly products and embracing direct-to-consumer business models. Innovations in AI-driven tools and sustainable practices have become key differentiators in this space. Strategic mergers and acquisitions are also accelerating competition, as companies work to expand their market share and enhance their technological capabilities.

Industry Updates

In June 2023, L’Oréal S.A. launched My Hair [iD], a hair color diagnosis app. It is designed by Modiface Technology, and the app tackles the unpredictability of hair color results. Users can virtually try a range of colors without perpetuating it.
In June 2023, L’Oréal S.A. started a campaign for its all-new iNOA hair color range. The 360-degree marketing campaign was launched using digital, social media, influencers, premium salons, and multi-city events.

Leading Customizable Hair Dye Brands

eSalon
Madison Reed
Function of Beauty
oVertone
Arctic Fox
Lime Crime
Good Dye Young
Brite Organix
Punky Colour
Splat Hair Color
Ion Color Brilliance
Manic Panic
Color&Co
Clairol Professional
Garnier Nutrisse Color Reviver

Tap into Expertise: Discuss with Our Analyst on Email: sales@futuremarketinsights.com

Key Segments of Market Report

By Product Type:

Based on product type, the industry is classified into permanent, semi-permanent, demi-permanent, bleach-highlights, and temporary.

By Form:

Depending on form, the sector bifurcates into powder and liquid.

By Sales Channel:

Customizable hair dyes are available in supermarkets/hypermarkets, departmental stores, convenience stores, online retailers, and others.

By Region:

Regional analysis of the industry has been conducted in the countries of North America, Latin America, Europe, East Asia, South Asia & Pacific, Middle East & Africa (MEA).

About Future Market Insights (FMI)

Contact Us: